Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pat...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a418c832eb2f477cb6afc86424d80a53 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a418c832eb2f477cb6afc86424d80a53 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a418c832eb2f477cb6afc86424d80a532021-11-25T17:04:28ZImmunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions10.3390/cancers132258272072-6694https://doaj.org/article/a418c832eb2f477cb6afc86424d80a532021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5827https://doaj.org/toc/2072-6694Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents. Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL.Dipenkumar ModiBindu PotugariJoseph UbertiMDPI AGarticlediffuse large B-cell lymphoma (DLBCL)autologous stem cell transplant (autoSCT)allogeneic stem cell transplant (alloSCT)CAR T-cell therapybispecific T-cell engager antibodyimmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5827, p 5827 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
diffuse large B-cell lymphoma (DLBCL) autologous stem cell transplant (autoSCT) allogeneic stem cell transplant (alloSCT) CAR T-cell therapy bispecific T-cell engager antibody immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
diffuse large B-cell lymphoma (DLBCL) autologous stem cell transplant (autoSCT) allogeneic stem cell transplant (alloSCT) CAR T-cell therapy bispecific T-cell engager antibody immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dipenkumar Modi Bindu Potugari Joseph Uberti Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions |
description |
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents. Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL. |
format |
article |
author |
Dipenkumar Modi Bindu Potugari Joseph Uberti |
author_facet |
Dipenkumar Modi Bindu Potugari Joseph Uberti |
author_sort |
Dipenkumar Modi |
title |
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions |
title_short |
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions |
title_full |
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions |
title_fullStr |
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions |
title_full_unstemmed |
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions |
title_sort |
immunotherapy for diffuse large b-cell lymphoma: current landscape and future directions |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/a418c832eb2f477cb6afc86424d80a53 |
work_keys_str_mv |
AT dipenkumarmodi immunotherapyfordiffuselargebcelllymphomacurrentlandscapeandfuturedirections AT bindupotugari immunotherapyfordiffuselargebcelllymphomacurrentlandscapeandfuturedirections AT josephuberti immunotherapyfordiffuselargebcelllymphomacurrentlandscapeandfuturedirections |
_version_ |
1718412731002912768 |